QSAR analysis of isosteviol derivatives as α-glucosidase inhibitors with element count and other descriptors

Letters in Drug Design and Discovery

Volumn 8, Issue 1, 2011, Pages 14-25

  Hari Narayana Moorthy, N S ^a   Ramos, Maria J ^a   Fernandes, Pedro A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

glucosidase inhibitor; Glycoprotein; Hydrophobicity; Isosteviol; Nitrogen count; QSAR

Indexed keywords

ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ISOSTEVIOL DERIVATIVE; NITROGEN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL BOND; ENZYME INHIBITION; HYDROPHILICITY; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 78650861840     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011793663859     Document Type: Article

References (44)

1. Kavitha, B.; Nagakumar, B.; Ki, H.P.; Keun, W.L. Binding mode analyses and pharmacophore model development for sulphonamide chalcone derivatives, a new class of α-glucosidase inhibitors. J. Mol. Graph. Model., 2008, 26, 1202-1212.
2. Woo, D.S.; Jin, H.K.; Jae, E.K.; Hyung, W.R.; Marcus, J.C.L.; Hyun, S.L.; Min, S.Y.; Ki, H.P. Sulfonamide chalcone as a new class of α-glucosidase inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 5514-5516.
3. Marie-Jeanne, P.O.; Rym, B.; Re Gis, G.; Marie, P.K.; Emmanuel, F. The glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step. Mol. Pharmacol., 2002, 61, 186-193.
4. Silva, C.H.T.P.; Taft, C.A. Computer aided molecular design of novel glucosidase inhibitors for AIDS treatment. J. Biomol. Struct. Dyn., 2004, 22, 59-63.
5. Jacinta, A.L.; Timm, M.; Wolfgang, L.; Volker, H.; Norbert, S. Crystal structure of Thermotoga maritime α-glucosidase AglA defines a new clan of NAD+ dependent glucosidases. J. Biol. Chem., 2003, 278, 19151-19158.
6. Sirichai, A.; Kasem, S.; Sophon, R.; Amron, P.; Nattaya, N.; Warinthorn, C.; Sujitra, D.; Siruntorn, Y. Structure activity relationships of trans-cinnamic acid derivatives on α-glucosidase inhibition. Bioorg. Med. Chem. Lett., 2004, 14, 2893-2896.
7. Debra, T.; Mohinder, S.K.; Tara, M.B.; Gordon, B.; Prasad, S.S.; Stanley, T. Inhibition of α-glucosidase I of the glycoproteinprocessing enzymes by 6-0-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob. Agents Chemother., 1994, 38, 1780-1787.
8. Tomich, C.H.; da Silva, P.; Ivone, C.; Taft, C.A. Homology modeling and molecular interaction field studies of α-glucosidase as a guide to structure based drug design of novel proposed anti-HIV inhibitors. J. Comput. Aided Drug Des., 2005, 19, 83-92.
9. Yan, L.; Zhuofeng, K.; Jianfang, C.; Wen-Hua, C.; Lin, M.; Bo, W. Synthesis, inhibitory activities and QSAR study of xanthone derivatives as α-glucosidase inhibitors. Bioorg. Med. Chem., 2008, 16, 7185-7192.
10. Ya, W.; Jing-Hua, Y.; Gui-Fu, D.; Cong-Jun, L.; Guo-Qiang, T.; Wen-Yan, M.; Jing-Chao, T. Stereoselective synthesis of bioactive isosteviol derivatives as α-glucosidase inhibitors. Bioorg. Med. Chem., 2009, 17, 1464-1473.
11. Melis, M.S. Renal excretion of stevioside in rats. J. Nat. Prod., 1992, 55, 688-690.
12. Chang, S.F.; Yang, L.M.; Lo, C.H.; Liaw, J.H.; Wang, L.H.; Li, S.J. Microbial transformation of isosteviol and bioactivities against the glucocorticoid/androgen response elements. J. Nat. Prod., 2008, 71, 87-92.
13. Yasukawa, K.; Kitanika, S.; Seo, S. Inhibitory effect of stevioside on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two stage carcinogenesis in mouse skin. Biol. Pharm. Bull., 2002, 25, 1488-1490.
14. Chem BioOffice 2008, CambridgeSoft Corp, UK, 2008.
15. V-Life Technologies, molecular design suite TM 3.5, Pune, India, 2008.
16. Statistica 8.0 statistical software, StatSoft, Inc. USA, 2008.
17. Balaji, S.; Karthikeyan, C.; Moorthy, N.S.H.N.; Trivedi, P. QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P-VSA and pharmacophore feature descriptors. Bioorg. Med. Chem. Lett., 2004, 14, 6089-6094.
18. Agrawal, V.K.; Srivastava, R.; Khadikar, P.V. QSAR studies on some antimalarial sulfonamides. Bioorg. Med. Chem., 2001, 9, 3287-3293.
19. Karthikeyan, C.; Moorthy, N.S.H.N.; Trivedi, P. QSAR study of substituted 2-pyridinyl quanidine as selective uro kinase-type plasminogen activator (uPA) inhibitors. J. Enzyme Inhib. Med. Chem., 2009, 24, 6-13.
20. Cho, D.H.; Lee, S.K.; Kim, B.T.; No, K.T. Quantitative structure activity relationship (QSAR) study of new fluorovinyloxyacetamides. Bull. Korean Chem. Soc., 2001, 22, 388-394.
21. Durbin, J.; Watson, G.S. Testing for serial correlation in least squares regression. II. Biometrika, 1951, 38, 159-178.
22. Gramatica, P. Principle of QSAR model validation: internal and external. QSAR Comb. Sci., 2007, 26, 694-701.
23. Tropsha, A.; Gramatica, P.; Gombar, V.K. The importance of earnest, validation is the absolute essential application and interpretation of QSPR models. QSAR Comb. Sci., 2003, 22, 69-77.
24. Erikkson, L.; Jaworsha, J.; Worth, A.P.; Mark, T.D.C.; Robert, M.M.; Gramatica, P. Methods for reliability and uncertainty assessment and for applicability evaluation of classification and regression based QSARs. Environ. Health Perspect., 2003, 111, 1361-1375.
25. Alexander, G.; Alexander, T. Beware of Q2. J. Mol. Graph. Model., 2002, 20, 269-276.
26. Cook, R.; Dennis. Influential observation in linear regression. J. Am. Stat. Assoc. 1979, 74, 169-174.
27. Rodriquez, G. Linear models for continuous data, Chapter 2. 1993-2000, pp. 49-58 (http://data.princeton.edu/wws509/notes).
28. Dogra; Shailay, K. Script for computing linear regression diagnostics from QSAR world-free online resources for QSAR modelling. (http://www.qsarworld. com/virtualworkshop.php.
29. Prasanna, S.; Manivannan, E.; Chaturvedi, S.C. QSAR analyses of conformationally restricted 1,5-diaryl pyrazoles as selective COX-2 inhibitors: application of connection table representation of ligands. Bioorg. Med. Chem. Lett., 2005, 15, 2097-2102.
30. Sanner, M.F.; Olson, A.J.; Spehner, J.C. Reduced surface: an efficient way to compute molecular surfaces. Biopolymer, 1996, 38, 305-320.
31. Hou, T.J.; Xu, X.J. ADME evaluation in drug discovery. 2. Prediction of partition coefficient by atom-additive approach based on atom-weighted solvent accessible surface areas. J. Chem. Inf. Comput. Sci., 2003, 43, 1058-1067.
32. Audry, E.; Dubost, J.P.; Colleter, J.C.; Dallet, P. A new approach of structure activity relationships: The 'potential of molecular lipophilicity. Eur. J. Med. Chem., 1986, 21, 71-72.
33. Nys, G.G.; Rekker, R.F. Statistical analysis of a series of partition coefficients with special reference to the predictability of folding of drug molecules. Introduction of hydrophobic fragmental constants (f-values). Chim. Therap., 1973, 8, 521-535.
34. Nys, G.G.; Rekker, R.F. The concept of hydrophobic fragmental constants (f-values) II. Extension to its applicability to the calculation of lipophiIicities of aromatic and heteroaromatic structures. Eur. J. Med. Chem-Chim. Therap., 1974, 9, 361-375.
35. Mannhold, R.; van de Waterbeemed. Substructure and whole molecule approaches for calculating log P. J. Comput. Aided Mol. Des., 2001, 15, 337-354.
36. Kellogg, G.E.; Semus, S.F.; Abraham, D.J.; HINT - A new method of empirical hydrophobic field calculation for CoMFA. J. Comput. Aided Mol. Des., 1991, 5, 545-552.
37. Kellogg, G.E.; Joshi, G.S.; Abraham, D.J. New tools for modeling and understanding hydrophobicity and hydrophobic interactions. Med. Chem. Res., 1992, 1, 444-453.
38. Kellogg, G.E.; Abraham, D.J. KEY, LOCK, and LOCKSMITH. Complementary hydrophobicity map predictions of drug structure from a known receptor/receptor structure from known drugs. J. Mol. Graphics, 1992, 10, 212-217.
39. Meng, E.C.; Kuntz, I.D.; Abraham, D.J.; Kellogg, G.E. Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicities. J. Comput. Aided Mol. Des., 1994, 8, 299-306.
40. Kellogg, G.E.; Abraham, D.J. Hydrophobicity: Is LogPo/w more than the sum of its parts?. Eur. J. Med. Chem., 2000, 35, 651-661.
41. Kellogg, G.E.; Abraham, D.J. Development of empirical biomolecular interaction models that incorporate hydrophobicity and hydropathy. The HINT paradigm. Analysis, 1999, 27, 19-22.
42. Durbin, J.; Watson, G.S. Testing for serial correlation in least squares regression.1. Biometrika, 1950, 37, 409-428.
43. Guha, R.; Van Drie, J.H. Structure-activity landscape index: Identifying and quantifying activity cliffs. J. Chem. Inf. Model., 2008, 48, 646-658.
44. Casalegno, M.; Sello, G.; Benfenati, E. Definition and detection of outliers in chemical space. J. Chem. Inf. Model., 2008, 48, 1592-1601.